[1]谢家印,王东,牟江洪,等.外周T细胞淋巴瘤APE1和P53蛋白联合表达的临床意义[J].第三军医大学学报,2009,31(06):510-514.
 XIE Jia-yin,WANG Dong,MOU Jiang-hong,et al.Coexpression and clinical significance of APE1 and P53 in peripheral T-cell lymphomas: report of 178 cases[J].J Third Mil Med Univ,2009,31(06):510-514.
点击复制

外周T细胞淋巴瘤APE1和P53蛋白联合表达的临床意义(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
31卷
期数:
2009年第06期
页码:
510-514
栏目:
论著
出版日期:
2009-03-30

文章信息/Info

Title:
Coexpression and clinical significance of APE1 and P53 in peripheral T-cell lymphomas: report of 178 cases
作者:
谢家印王东牟江洪肖华亮李梦侠向德兵仲召阳王阁
第三军医大学大坪医院野战外科研究所:肿瘤中心,病理科
Author(s):
XIE Jia-yin WANG Dong MOU Jiang-hong XIAO Hua-liang LI Meng-xia XIANG De-bing ZHONG Zhao-yang WANG Ge
Tumor Center, Department of Pathology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing 400042, China
关键词:
淋巴瘤外周T细胞APE1P53预后
Keywords:
lymphomas peripheral T-cell APE1 P53 prognosis
分类号:
R394.2;R730.23;R730.263
文献标志码:
A
摘要:
目的    研究外周T细胞淋巴瘤(peripheral T-cell lymphomas,PTCLs)APE1和P53蛋白联合表达与临床特征、化疗效果及预后的关系。    方法    免疫组化法检测178例PTCLs患者瘤细胞APE1和P53蛋白表达情况,采用单因素和多因素分析比较APE1和P53蛋白表达及联合表达与临床特征、预后的关系。    结果    PTCLs患者APE1和P53蛋白表达阳性率分别为82.6%(147/178)和40.5%(72/178),其中血管免疫母T细胞淋巴瘤(ATL)和外周T细胞淋巴瘤-非特异型(PTCL-U)患者的APE1表达阳性率显著高于结外NK/T细胞淋巴瘤(NK/TL)、皮下脂膜炎样T细胞淋巴瘤(CTCL)和间变大T细胞淋巴瘤(ALCL)患者(P<0.05)。具有APE1+/P53+共表达患者的临床分期以Ⅲ+Ⅳ为主,中、高危患者比例高;APE1+/P53+组与APE1+/P53+组患者化疗疗效显著低于APE1-/P53-组和APE1-/P53+组(P<0.01);APE1+/P53-组和APE1+/P53+组患者总生存率明显低于APE1-/P53- 和APE1-/P53+2组(P<0.01),APE1+/P53+组患者无病生存时间(DFS)明显低于其他3组(P<0.01);单因素生存分析显示APE1及P53呈阳性表达、APE1+/P53-和APE1+/P53+联合表达与患者预后不良有关(P<0.05),APE1+/P53- 和APE1+/P53+联合表达均与3年生存率有关(P<0.05,P<0.01);多因素生存分析显示APE1+/P53+共表达患者预后最差(P<0.01)。    结论    APE1、P53表达阳性,以及APE1+/P53-、APE1+/P53+联合表达的患者预后不良;APE1+/P53+共表达为PTCLs患者独立预后因素。
Abstract:
Objective    To study the relationship of the coexpression of APE1 and P53 with clinical related-parameters of the stages, international prognostic indexes, chemotherapeutic efficacy and prognosis in peripheral T-cell lymphomas (PTCLs).     Methods    Totally lymphoma specimens from 178 PTCLs patients were collected including 90 cases of peripheral T-cell lymphoma-unspecified (PTCL-U), 42 of extranodal NK/T cell lymphoma(NK/TL), 22 of anaplastic large T-cell lymphoma (ALCL), 20 of angioimmuno-blastic T-cell lymphoma (ATL), and 4 of   subcutaneous panniculitis-like T-cell lymphoma(CTCL). Expressions of APE1 and P53 were detected with immunohistochemical method in these 178 specimens. The correlations of the expressions of APE1 and P53 alone or combined together with the clinical features as well as prognosis were statistically analyzed with univariate and multivariate analyses.     Results    The APE1 expression and the P53 expression were positive in 147(82.6%) and 72 of 178 cases (40.5%) respectively. The positive rate of APE1 in the patients with ATL and PTCL-U was significantly higher than that in the patients with NK/TL, CTCL and ALCL (P<0.05). Most patients with the APE1+/P53+ coexpression were belonged to stage Ⅲ and Ⅳ and intermediate or high risk condition. The response rates of the patients in APE1+/P53- group and APE1+/P53+ group were very lower than those of the patients in APE1-P53- group and APE1-P53+ group (P<0.01),  meanwhile, the survival rates in APE1+/P53- group and PE1+/P53+group were significant lower than those in APE1-/P53- group and APE1-/P53+ group(P<0.01). The disease-free survival time in APE1+/P53+ group was very lower than that in the other 3 groups (P<0.01). Univariate analysis showed that the positive expressions of APE1 or P53 and coexpression of APE1+/P53- and APE1+/P53+ were significantly correlated with the poor prognosis all together (P<0.05), and the coexpressions of APE1+/P53- and APE1+/P53+ were with 3-years survival rate respectively (P<0.05 and P<0.01). Multivariate analysis with the Cox regression models showed that the coexpression of APE1+/P53+ was significantly associated with the poor prognosis(P<0.01).     Conclusion    The respective expression of APE1+ or P53+, the coexpression of APE1+/P53- and APE1+/P53+ are indicators of the poor prognosis in PTCLs patients; What’s more, the coexpression of APE1+/P53+ may be also a independent prognosis factor for PTCLs.

参考文献/References:

谢家印, 王东, 牟江洪, 等. 外周T细胞淋巴瘤APE1和P53蛋白联合表达的临床意义[J]. 第三军医大学学报, 2009, 31(6):510-514.

相似文献/References:

[1]苏毅,赖思含,易海,等.异基因造血干细胞移植术治疗自体造血干细胞移植术后复发的恶性淋巴瘤17例效果分析[J].第三军医大学学报,2012,34(24):2456.
 Su Yi,Lai Sihan,Yi Hai,et al.Allogeneic hematopoietic stem cell transplantation for recurrent lymphoma after autologous stem cell transplantation: clinical analysis of 17 cases[J].J Third Mil Med Univ,2012,34(06):2456.
[2]黄英辉,张立,黄艳,等.α/β干扰素通过上调SARI表达抑制淋巴瘤细胞的增殖[J].第三军医大学学报,2012,34(24):2465.
 Huang Yinghui,Zhang Li,Huang Yan,et al.Interferon-α/β inhibits lymphoma cell proliferation by up-regulating SARI expression[J].J Third Mil Med Univ,2012,34(06):2465.
[3]张晓梅,张桂英,王娟.胃黏膜相关淋巴组织淋巴瘤的内镜下表现[J].第三军医大学学报,2008,30(05):457.
[4]宋强,郑伟刚,卢贺华.胃黏膜相关性淋巴组织淋巴瘤1例[J].第三军医大学学报,2008,30(08):686.
[5]刘静,张伟京,苏航.间变性大细胞淋巴瘤19例临床特征分析[J].第三军医大学学报,2008,30(11):997.
[6]谌琴,何冬梅.人pre-miR-15a真核表达载体的构建及其对Raji细胞生长的抑制作用[J].第三军医大学学报,2009,31(23):2334.
 CHEN Qin,HE Dong-mei.Construction of eukaryotic expression vector of pre-miR-15a and its inhibitory effect on Raji cells proliferation[J].J Third Mil Med Univ,2009,31(06):2334.
[7]陈泽林,王祥卫,康俊.原发性睾丸非霍奇金淋巴瘤1例[J].第三军医大学学报,2010,32(05):453.
[8]王光宪,张冬,王文献,等.肾脏继发性淋巴瘤的CT诊断价值[J].第三军医大学学报,2011,33(19):2043.
 Wang Guangxian,Zhang Dong,Wang Wenxian,et al.Value of CT in the diagnosis of renal secondary lymphoma[J].J Third Mil Med Univ,2011,33(06):2043.
[9]王燕青.三阶梯护理措施预防淋巴瘤患者化疗相关院内感染的效果评价[J].第三军医大学学报,2010,32(09):996.
[10]王光宪,舒健,钟维佳,等.16层CT在继发性肺淋巴瘤中的诊断价值[J].第三军医大学学报,2010,32(06):601.
 Wang Guangxian,Shu Jian,Zhong Weijia,et al.CT findings of secondary pulmonary lymphoma: report of 20 cases[J].J Third Mil Med Univ,2010,32(06):601.

更新日期/Last Update: 2009-03-24